Press release
Transthyretin Amyloidosis Treatment Market Growth, Size, Overview By 2024-2033
"The new report published by The Business Research Company, titled ""Transthyretin Amyloidosis Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.As per the report, the transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The transthyretin amyloidosis treatment market size is expected to see strong growth in the next few years. It will grow to $7.42 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%.
Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp
Increased Research And Development Investments Propel Growth In The Transthyretin Amyloidosis Treatment Market
Rising investments in research and development are expected to propel the growth of the transthyretin amyloidosis treatment market going forward. Research and development (R&D) investments include financial resources allocated to activities aimed at advancing scientific knowledge, developing new technologies, creating innovative products, and improving existing processes. Increased funding in research and development enables the discovery and development of innovative treatment approaches for transthyretin amyloidosis, including novel drugs, gene therapies, and precision medicine techniques, offering patients more effective and targeted treatment options. For instance, in December 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company engaged in the development of Vutrisiran, a treatment of ATTR amyloidosis, increased its research and development investment to $883,015 in 2022 from $792,156 in 2021, reflecting a growth of 11.49%. Therefore, the rising investment in research and development will drive the growth of the transthyretin amyloidosis treatment market.
Innovative Orphan Drug Combinations Transforming The Landscape Of Transthyretin Amyloidosis Treatment
Major companies in the transthyretin amyloidosis treatment market focus on developing innovative and specialized treatments, such as orphan drugs, to enhance patient outcomes and expand treatment options. Eplontersen is an orphan drug specifically designed to treat transthyretin amyloidosis condition, often receiving regulatory benefits to support its development. For instance, in March 2023, Ionis Pharmaceuticals, Inc., a Canada-based biotechnology research company, received The Food and Drug Administration (FDA) approval of a new drug application for Eplontersen, an experimental orphan drug intended for the treatment of familial transthyretin-mediated amyloid, leading to progressive polyneuropathy. Eplontersen is a pharmaceutical agent developed to mitigate the synthesis of transthyretin (TTR) protein to address both the hereditary and non-hereditary variations of ATTR amyloidosis (amyloid transthyretin amyloidosis). The FDA granted Eplontersen orphan drug designation in 2022.`
The transthyretin amyloidosis treatment market covered in this report is segmented -
1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13129&type=discount
Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc, Abbvie Inc, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, GSK Plc, Novo Nordisk A/S, Merck & Co. Inc, Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc, PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc, Acrotech Biopharma Inc, Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc, Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A
Contents of the report:
1. Executive Summary
2. Transthyretin Amyloidosis Treatment Market Report Structure
3. Transthyretin Amyloidosis Treatment Market Trends And Strategies
4. Transthyretin Amyloidosis Treatment Market - Macro Economic Scenario
5. Transthyretin Amyloidosis Treatment Market Size And Growth
…..
27. Transthyretin Amyloidosis Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Transthyretin Amyloidosis Treatment Market Growth, Size, Overview By 2024-2033 here
News-ID: 3575407 • Views: …
More Releases from The Business research company

Comprehensive Drone-Assisted Forest Firebreak Planning Market Forecast 2025-2034 …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Drone-Assisted Forest Firebreak Planning Market Through 2025?
The market for drone-aided forest fire prevention planning has seen an impressive explosion in growth in the recent past. The market, now estimated at $1.32 billion in 2024, is projected to rise to $1.62 billion…

Global Credit Score Tracking Service Market Projected to Grow at 12.2% CAGR, Rea …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Credit Score Tracking Service Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The industry for monitoring credit scores has seen a swift expansion in the recent past. It is projected to escalate from $2.75 billion in 2024 to $3.09 billion in 2025, with a CAGR…

Rising Popularity Of Digital Wallets Driving The Market Growth Due To Increasing …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Doorstep Banking Software Market Size By 2025?
The market size of doorstep banking software has experienced significant expansion in the previous years. It is projected to ascend from $1.97 billion in 2024 to approximately $2.28 billion in 2025. This suggests a compound annual growth rate…

Corporate Insolvency Service Market: Major Trends Reshaping the Future of the In …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Corporate Insolvency Service Market Through 2025?
The market size of the corporate insolvency service has seen significant growth in the past few years. The projected growth from $11.55 billion in 2024 to $12.45 billion in 2025, with a compound annual growth rate…
More Releases for Transthyretin
Evolving Market Trends In The Transthyretin Amyloidosis Treatment Industry: Inno …
The Transthyretin Amyloidosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Transthyretin Amyloidosis Treatment Market Size During the Forecast Period?
The market for transthyretin amyloidosis treatments has witnessed significant growth in the past few years. The market, which was valued at…
What's Driving the Transthyretin Amyloidosis Treatment Market 2025-2034: Increas …
What Are the Projections for the Size and Growth Rate of the Transthyretin Amyloidosis Treatment Market?
The market for transthyretin amyloidosis treatment has seen robust growth in the past years. Its size is forecasted to increase from $5.52 billion in 2024 to $5.95 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The surge in the market over the historic period is due to increased disease awareness, progress…
Transthyretin Amyloid Cardiomyopathy Market Statistical Forecast, Trade Analysis …
DataM Intelligence has published a new research report on "Transthyretin Amyloid Cardiomyopathy Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF…
Unveiling Transthyretin Amyloidosis Treatment Market 2024
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research..
The transthyretin amyloidosis treatment market size is…
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals…
Anti-Transthyretin Global Market Research Report 2025
Anti-Transthyretin Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
Access more details about this report at: https://www.research2reports.com/report-medical-devices/anti-transthyretin-market/80994
The report firstly introduced the Anti-Transthyretin basics: definitions, classifications, applications and market overview;…